SCHEMBL2397916

SCHEMBL2397916

O=C(NCc1ccc(Oc2ccc(OC(F)(F)F)cc2)cc1)c1ncn(-c2cc(Cl)c(O)c(Cl)c2)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B13 Q7Z5P4 2/20 0.47
KLKB1 P03952 2/20 0.46
KLK1 P06870 1/20 0.46
CYP2C9 P11712 5/20 0.43
ALDH1A1 P00352 4/20 0.43
HPGD P15428 4/20 0.43
CYP2C19 P33261 3/20 0.43
CYP1A2 P05177 2/20 0.43
CYP2D6 P10635 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
KDM4E B2RXH2 3/20 0.43
EPHX2 P34913 2/20 0.42
NR1H4 Q96RI1 1/20 0.42
GAA P10253 1/20 0.42
PTGER4 P35408 2/20 0.42
HTR2C P28335 1/20 0.42
MAPK14 Q16539 1/20 0.42
PDE2A O00408 1/20 0.41
CYP3A4 P08684 2/20 0.41
NOTUM Q6P988 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2398093 0.89 KLKB1 (0.45) HSD17B13KLKB1KLK1MAPK14NOTUM
SCHEMBL2397861 0.89 KLKB1 (0.49) HSD17B13KLKB1KLK1HPGDSMN1; SMN2
SCHEMBL2213974 0.89 KLKB1 (0.59) KLKB1KLK1ALDH1A1HPGDSMN1; SMN2
SCHEMBL2398166 0.88 KLKB1 (0.44) KLKB1KLK1EPHX2HTR2CMAPK14
SCHEMBL2212039 0.87 ABCB1 (0.51) HSD17B13MAPK14
SCHEMBL2398518 0.87 KLKB1 (0.46) KLKB1KLK1CYP2C19CYP1A2EPHX2
SCHEMBL2220555 0.87 KLKB1 (0.46) KLKB1KLK1SMN1; SMN2PTGER4MAPK14
SCHEMBL2214888 0.87 KLKB1 (0.43) HSD17B13KLKB1KLK1PTGER4MAPK14
SCHEMBL12262951 0.85 KLKB1 (0.42) KLKB1KLK1CYP2C19CYP1A2SMN1; SMN2
SCHEMBL2398104 0.85 KLKB1 (0.46) KLKB1KLK1ALDH1A1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110237528-A1 COMPOSITIONS AND METHODS COMPRISING IMIDAZOLE AND TRIAZOLE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH (US) 2011-09-29 US claimed
US-20110237528-A1 COMPOSITIONS AND METHODS COMPRISING IMIDAZOLE AND TRIAZOLE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH (US) 2011-09-29 US disclosed
US-20110237528-A1 COMPOSITIONS AND METHODS COMPRISING IMIDAZOLE AND TRIAZOLE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH (US) 2011-09-29 US disclosed
US-20110237528-A1 COMPOSITIONS AND METHODS COMPRISING IMIDAZOLE AND TRIAZOLE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH (US) 2011-09-29 US disclosed
US-20100144733-A1 Compounds, compositions and methods comprising heteroaromatic derivatives INSTITUTE FOR ONEWORLD HEALTH 2010-06-10 US disclosed
US-20100144733-A1 Compounds, compositions and methods comprising heteroaromatic derivatives INSTITUTE FOR ONEWORLD HEALTH 2010-06-10 US disclosed
US-20100144733-A1 Compounds, compositions and methods comprising heteroaromatic derivatives INSTITUTE FOR ONEWORLD HEALTH 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144733-A1 Compounds, compositions and methods comprising heteroaromatic derivatives CFTR, PKD1, PKD2 HSD17B13 924/4885KLKB1 2055/4885KLK1 1664/4885
US-20110237528-A1 COMPOSITIONS AND METHODS COMPRISING IMIDAZOLE AND TRIAZOLE DERIVATIVES CFTR, PKD1, PKD2 HSD17B13 2192/4885KLKB1 1321/4885KLK1 1339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.